- By ICR Secretariat
- Posted Wednesday, May 3, 2023
Immuneering reveals positive data from tumour treatment trial
https://www.pharmatimes.com/news/immuneering_reveals_positive_data_from_tumour_treatment_trial_1490859
Immuneering – a company developing medicines for cancer patients – has announced positive pharmacodynamic (PD) and pharmacokinetic (PK) safety data from its phase 1 trial.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- Future of Intercept’s NASH drug in doubt after FDA panel rejection 30/05/2023 03:56 PM
- 'The Top Line': 2023's biopharma layoffs, plus this week's headlines 30/05/2023 03:55 PM
- How the digital front door benefits clinical trial patients, clinicians and sponsors 30/05/2023 03:53 PM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org